Piper Jaffray Companies set a $55.00 price target on Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note released on Thursday morning. The firm currently has a buy rating on the stock.
Several other brokerages also recently weighed in on PCRX. Canaccord Genuity set a $45.00 price objective on shares of Pacira Pharmaceuticals and gave the company a hold rating in a research report on Tuesday, September 4th. Wedbush reiterated an outperform rating and issued a $80.00 price objective (down from $85.00) on shares of Pacira Pharmaceuticals in a research report on Monday, August 6th. ValuEngine upgraded shares of Pacira Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, October 18th. Cowen reiterated a hold rating on shares of Pacira Pharmaceuticals in a research report on Tuesday, July 10th. Finally, Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, July 4th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $51.56.
Shares of Pacira Pharmaceuticals stock traded down $1.84 during trading hours on Thursday, reaching $50.32. The company’s stock had a trading volume of 1,024,467 shares, compared to its average volume of 816,625. The company has a debt-to-equity ratio of 0.98, a quick ratio of 7.79 and a current ratio of 8.58. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $55.00. The company has a market cap of $2.01 billion, a P/E ratio of -86.76 and a beta of 1.87.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.40. The company had revenue of $83.45 million for the quarter, compared to the consensus estimate of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 3.64% and a negative return on equity of 0.39%. The company’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same period last year, the firm posted $0.11 EPS. As a group, sell-side analysts predict that Pacira Pharmaceuticals will post -0.21 earnings per share for the current year.
In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 4,773 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $47.04, for a total transaction of $224,521.92. Following the transaction, the chief accounting officer now owns 22,374 shares of the company’s stock, valued at approximately $1,052,472.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Lauren Bullaro Riker sold 1,000 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $50.70, for a total transaction of $50,700.00. Following the completion of the transaction, the vice president now directly owns 11,474 shares in the company, valued at approximately $581,731.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,502 shares of company stock worth $1,913,864. 5.90% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. State of Wisconsin Investment Board grew its stake in shares of Pacira Pharmaceuticals by 3.0% in the 2nd quarter. State of Wisconsin Investment Board now owns 40,600 shares of the company’s stock worth $1,301,000 after purchasing an additional 1,200 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Pacira Pharmaceuticals by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 39,897 shares of the company’s stock worth $1,279,000 after purchasing an additional 1,335 shares during the last quarter. Summit Trail Advisors LLC grew its stake in shares of Pacira Pharmaceuticals by 12.9% in the 1st quarter. Summit Trail Advisors LLC now owns 15,103 shares of the company’s stock worth $400,000 after purchasing an additional 1,728 shares during the last quarter. US Bancorp DE grew its stake in shares of Pacira Pharmaceuticals by 40.7% in the 2nd quarter. US Bancorp DE now owns 6,038 shares of the company’s stock worth $194,000 after purchasing an additional 1,746 shares during the last quarter. Finally, Pendal Group Ltd grew its stake in shares of Pacira Pharmaceuticals by 9.3% in the 2nd quarter. Pendal Group Ltd now owns 23,326 shares of the company’s stock worth $748,000 after purchasing an additional 1,975 shares during the last quarter.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Further Reading: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.